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Background: Robot-assisted radical cystectomy (RARC) with intracorporeal diversion has been shown to be feasible
in a few centers of excellence worldwide, with promising functional and oncologic outcomes. However, it remains
unknown whether the complexity of the procedure allows its duplication in other non-pioneer centers. We attempt
to address this issue by presenting our cumulative experience with RARC and intracorporeal neobladder formation.
Methods: We retrospectively identified 62 RARCs in 50 men and 12 women (mean age 63.6 years) in two tertiary
centers. Intracorporeal Studer neobladders were created, duplicating the steps of standard open surgery.
Perioperative and postoperative variables and complications were analyzed using standardized tools. Functional and
oncological results were assessed.
Results: The mean operative time was 476.9 min (range, 310 to 690) and blood loss was 385 ml (200 to 800). The
mean hospital stay was 16.7 (12 to 62) days with no open conversion. Perioperative complications were grade II in
15, grade III in 11, and grade IV in 5 patients. The mean nodal yield was 22.9 (8 to 46). Positive margins were found
in in 6.4%. The 90- and 180-day mortality rates were 0% and 3.3%. The average follow-up was 37.3 months (3 to
52). Continence was achieved in 88% of patients. The cancer-specific survival rate and overall survival rate were 84%
and 71%, respectively.
Conclusions: A RARC with intracorporeal neobladder creation is safe and reproducible in ‘non-pioneer’ tertiary
centers with robotic expertise with acceptable operative time and complications. Further standardization of RARC
with intracorporeal diversion is a prerequisite for its widespread use.
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Radical cystectomy with pelvic lymph node dissection is
considered to be the most effective treatment of muscle-
invasive bladder cancer. Moreover, it is an option in
high-grade non-muscle-invasive disease refractory to
intravesical instillation therapy. In the majority of cases,
the most popular choice of diversion is either an ileal
conduit or an orthotopic neobladder. Open radical cyst-
ectomy is still regarded as the gold standard treatment* Correspondence: erdcand@yahoo.com.tr
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muscle-invasive bladder cancer. However, minimally in-
vasive radical cystectomy techniques have recently been
gaining popularity and robot-assisted technique is used
in most cases nowadays. Robot-assisted radical cystec-
tomy (RARC) has been shown to be equivalent to open
radical cystectomy in terms of oncological and func-
tional outcomes and to be superior when it comes to
perioperative outcomes, such as hospital stay and blood
loss [1-5]. Surrogate parameters, such as nodal yield and
positive surgical margins have been used to compare
oncological outcomes with the open technique [2,5].
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corporeally to shorten operating time. Hence, RARC and
urinary diversion could at best be regarded as a hybrid
approach. Jonsson and associates [6] have pioneered the
technique of intracorporeal urinary diversion, creating
both neobladders and ileal conduits completely intracor-
poreally. The technique is to be credited as an almost
identical replication of open surgical principles. Recently,
the group reported the oncologic and functional out-
comes of their RARC cohort showing comparable results
to open series [7]. Equally, Goh et al. presented remark-
able outcomes using a modification of the aforemen-
tioned technique [8]. As such, RARC and intracorporeal
urinary diversion are technically feasible with excellent
outcomes. However, these observations are limited to
very few pioneering centers worldwide. To date, it is un-
known whether RARC and intracorporeal diversion are
reproducible by other tertiary centers with robotic
expertise. In particular, intracorporeal neobladder forma-
tion is regarded as technically challenging and poten-
tially time-consuming with a steep learning curve [9,10].
Herein, we present a homogenous series of patients who
underwent RARC and subsequent intracorporeal neo-
bladder formation, with the techniques described by
Wiklund and colleagues [9,10]. Herewith, we aim to
demonstrate that a standardized technique of RARC and
intracorporeal neobladder is safely reproducible and
teachable, given adequate robotic experience.
Methods
We retrospectively identified 62 patients who underwent
RARC and orthotopic ileal neobladder formation in two
academic centers, Eberhard-Karls University Tübingen,
Germany, and Ankara Atatürk Training & Research Hospital,
Turkey, for the period October 2009 to October 2014.
A total of 300 radical cystectomies were performed dur-
ing this period. One surgeon from each center who was
experienced in open radical cystectomy as well as ro-
botic prostatectomy performed the RARC with intra-
corporeal neobladder construction. Institutional review
board approval was given before data analysis was started
(# 081/2014R). Indications for RARC were muscle-invasive
transitional carcinoma and non-muscle-invasive disease re-
fractory to intravesical instillation treatment. Both men and
women were included in the analysis. Patients receiving
ileal conduit diversion were excluded. Other exclusion cri-
teria were non-transitional-carcinoma histology, coagulopa-
thy, pre-existing incontinence, cerebrovascular disease, and
severe pulmonary dysfunction, rendering robotic surgery
impossible. Patients with previous intra-abdominal surger-
ies or radiotherapy were not excluded. Data analyzed in-
cluded perioperative variables (operating time, blood loss,
hospital stay), standardized complication reporting using
the Clavien-Dindo system [11], pathology reporting, andfunctional as well as oncologic outcomes. Furthermore, 90
and 180-day mortality are reported.
Surgical technique
The RARC was performed using a three-arm Da Vinci S
system (Intuitive Sunnyvale, CA, USA). One optical trocar
was placed 2 cm above the umbilicus and a 0 degree tele-
scope was used in all cases. The two remaining robotic
trocars were placed a handbreadth lateral to the umbilicus
and two more 12 mm assisting trocars were inserted 5 cm
above the anterior-superior iliac spine. Finally, a 5 mm
trocar was placed in the right upper abdomen. The RARC
was then performed as described previously in a steep
Trendelenburg position. Nerve sparing in both men and
women was attempted whenever oncologically sound. Ex-
tended pelvic node dissection included the external and
internal as well as the common iliac nodes, the obturator
fossa, and the presacral area, as described previously.
Para-aortic nodes were only removed when enlarged, in
order to preserve the hypogastric plexus as much as pos-
sible. The bladder specimen and the lymph nodes were
put into impermeable retrieval bags until removal at the
end. Both ureters were clipped early and the left ureter
was transposed below the sigmoid mesocolon. They were
then tagged to the lateral abdominal wall until reimplanta-
tion. The robot was undocked and the operating table was
flattened. The robot was redocked and a 50 cm loop of
terminal ileum was isolated approximately 25 cm proximal
to the ileocecal valve. The most dependent part was
opened and anastomosed to the urethral stump using a
running suture [6,9]. The ileal loop was then discontinued
using a 60 mm Endo-GIA stapler (Covidien, Mansfield,
MA, USA). Bowel continuity was then restored using a
stapled side-to-side anastomosis. The isolated loop was
consequently opened according to Studer, leaving a 15 cm
afferent segment. The posterior plate was then recon-
structed using a 3/0 absorbable suture in a running fash-
ion. The neobladder was then folded asymmetrically using
a technique previously described by Wiklund [6,9]. A 20
Fr Foley catheter was then advanced into the reservoir
and its water-tightness was tested. The ureters were con-
joined using the Wallace technique with a 4/0 absorbable
suture. Single-J stents were placed over guide wire and the
ends were advanced through the wall of the reservoir.
Both ureters were then anastomosed to the afferent limb
using a 4/0 absorbable suture. Stents were advanced to the
skin through the 12 mm trocar and two drains were
placed. Specimens were ultimately retrieved through a
separate incision. (Specimens were delivered via the vagina
in women.) Incisions were closed in layers.
Statistical analysis
Data are descriptively reported using mean and standard
deviation.
Table 2 Perioperative and postoperative outcome
Operating time, min, mean (range) 476.9 (310 to 690)
Diversion time, min, mean (range) 183.8 (144 to 300)
Blood loss, ml, mean (range) 385 (200 to 800)
Conversion (%) 0 (0)
Hospital stay, days, mean (range) 16.73 (12 to 62)
Nerve sparing, bilateral (%)
Men (%) 46/50 (92)







Table 3 Pathology characteristics
Postoperative pT-stage (%)
Carcinoma in situ 4 (6.5)
T0 6 (9.7)
T1 5 (8)
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In total, 62 RARCs with intracorporeal neobladder for-
mation were identified in 50 men and 12 women. The
mean age was 63.6 years (41 to 80). The mean body
mass index was 25.5 kg/m [2] (19 to 34). Studer neo-
bladders were hand-sewn in all cases, replicating the
open technique. Neoadjuvant chemotherapy was admin-
istered in nine patients with presumably advanced stage
(Table 1). All procedures were completed without open
conversion. The mean operating time was 476.9 min
(310 to 690) and blood loss was 385 ml (200 to 800)
while the mean diversion time was 183.8 minutes (140
to 300). The mean hospital stay was 16.7 (12 to 62) days.
In the last ten patients, the mean diversion time was
146.6 min with an overall surgical time of 372.5 min
(310 to 423). Bilateral nerve sparing was performed in
all women and in 46 out of 50 men (92%). Perioperative
complications were grade II in 15, grade III in 11, and
grade IV in 5 patients. There were no complications as-
sociated with patient positioning (Table 2). The overall
complication was 50%. Minor (Clavien I & II) and major
(Clavien ≥ III) complication rates were 24.2% and 25.8%
respectively. The postoperative tumor stage was carcin-
oma in situ in 4, pT0 in 6, pT1 in 5, pT2 in 23, pT3 in
18, pT4 in 6, and N+ in 15 patients and all were high-
grade disease. The mean nodal yield was 22.9 (8 to 46).
Positive margins were found in 6.4% of patients and all
were positive ureteric margins. Concomitant prostate
cancer was found in 14 men (28%). The Gleason score
was 3 + 3 in nine, 3 + 4 in four, and 4 + 3 in one patient,
respectively (Table 3). All but one man had a negative
margin (positive margin rate 7.1%). However, to date
there has not been any biochemical recurrence. The 90
and 180-day mortality rates were 0% and 3.3%. TheTable 1 Patients’ characteristics
Men (%) 50 (80.6)
Women (%) 12 (19.4)
Age, years, mean (range) 63.6 (41 to 80)
Body mass index, mean (range) 25.5 (19 to 34)
Preoperative stage (%)








Neoadjuvant chemotherapy (%) 9 (14.5%)
Previous Bacillus Calmette-Guérin instillation (%) 8 (12.9%)average follow-up period was 37.3 months (3 to 52).
Daytime continence could be achieved in 88% of pa-
tients while complete nighttime continence was noted in
58.1% of patients. Spontaneous erections were reported
from 27 men (54%). Ureteric strictures developed in
8.3% of patients and were the most frequent long-term
complication. Metastatic disease developed in 21% of









Lymph node count (range) 22.9 (8 to 46)
Positive margins, % 6.4
Concomitant prostate cancer (%) 14 (22.6)
Gleason score (%)
Gleason 6 9 (64.3)
Gleason 7a (Gleason 3 + 4) 4 (28.6)
Gleason 7b (Gleason 4 + 3) 1 (7.1)
Positive margins (prostate) 7.1%
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ing the follow-up period, whereas five patients died from
other non-cancer-related disease. The cancer-specific
survival rate and overall survival rate were 84% and 71%,
respectively (Table 4).
Discussion
Robot-assisted radical cystectomy has been increasingly
advocated as a viable alternative to open radical cystec-
tomy. Despite a clear advantage with respect to peri-
operative morbidity and postoperative recovery, RARC
is still not widely used. This is in sharp contrast to the
widespread use of robotic radical prostatectomy. Initial
criticism was focused on the lack of oncologic outcome
data. Even though ultimate evidence may still be miss-
ing, recent reports confirm the long-term safety and effi-
cacy of laparoscopic radical cystectomy as well as of
RARC [5]. Surrogate parameters, such as nodal yield
and margin status have been used to show equivalent
oncological outcomes. Secondly, RARC has always been
considered a very lengthy procedure with the potential
risk of complications associated with the steep Trende-
lenburg position. This may be true for the initial series;
however, contemporary data indicate competitive surgi-
cal times [9]. Thirdly, RARC and neobladder diversion
has been deemed a cumbersome procedure, consisting
of a robotic part and an open extracorporeal part for
urinary diversion. Hence, many surgeons have ques-
tioned the point of performing RARC first followed by
open diversion, as this removes most advantages, such
as smaller wound incision and reduced bowel exposure.
Wiklund and colleagues have pioneered the technique of
intracorporeal neobladder formation following RARC.
They follow the principles of open surgery in creating a
Studer neobladder, including proper folding [12]. Their
approach has evolved, leading to technical modifications
and a reduction of complications and operation times.
In a cumulative analysis of 70 patients with a median
follow-up of 30.3 months, they found negative margins
in 98.6% of cases. Relevant complications occurred in
31.4% of patients at 30 days and 18.6% of patients at >30Table 4 Functional and oncologic outcomes




Erectile dysfunction (%) 46
Recurrences (%) 1 (1.6)
Distant metastasis (%) 13 (21)
Cancer-specific survival (%) 84
Overall survival (%) 71days. At 90 days, the overall complication rate was
58.5%. The recurrence-free, cancer-specific, and overall
survival rates at 24 months were 80.7%, 88.9%, and
88.9%, respectively. Daytime continence and satisfactory
sexual function or potency at 12 months ranged between
70% and 90% in both men and women. These results are
well in line with contemporary open-surgery results [7].
A retrospective comparison with open diversion in the
framework of the International Robotic Cystectomy
Consortium, including 935 patients, further confirmed
the safety of intracorporeal diversion by showing a lower
risk of postoperative complication, including gastrointes-
tinal complications in these patients [13]. Notably, only
61 patients had undergone intracorporeal neobladder
formation in this comparative study. In the USA, similar
approaches have been described. Although a shorter
follow-up time was recorded with fewer patients, excel-
lent results have been reported [8]. Herein, we present
our cumulative experience with RARC and intracorpor-
eal neobladder formation performed in two tertiary re-
ferral centers with robotic expertise. Surgery has been
performed according to previously published principles.
As such, our series represents a real-life experience of
intracorporeal diversion outside of the pioneering cen-
ters. Many findings by the pioneer group have been cor-
roborated and their results have been widely replicated.
Hence, RARC and intracorporeal neobladder formation
may be safely implemented in a clinical routine when-
ever adequate robotic experience is available. To the best
of our knowledge, our report describes the largest series
of RARC and intracorporeal diversion apart from the
Karolinska group. The fact that the results are compar-
able to those of the inventors of the approach may be of
particular value when it comes to assessment of teaching
and overcoming the learning curve. Importantly, the ap-
proach has now been transformed into a standardized
robotic procedure with well-defined steps. Obviously,
our surgical times in the initial cases were long, owing
to the learning curve. However, over time, the average
operative times could be reduced to less than 6 hours.
This is in line with the demonstration by various studies
that robotic cystectomy and intracorporeal neobladder
construction can be achieved safely with a structured ap-
proach in a high volume center [9,14].
The functional outcomes of patients who underwent
robotic cystectomy is quantified by continence and sex-
ual function. In our cases, continence is defined as usage
of less than one pad a day. The continence outcome is
usually measured at 12 months after surgery, as the as-
sessment is more accurate after the neobladder has
achieved its functional capacity. Similarly, sexual func-
tion is also measured at 12 months.
From our experience, another important element to a
successful RARC with intracorporeal neobladder that
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perioperative outcomes is a dedicated robotic team. An
RARC with intracorporeal diversion is extremely com-
plex and can be intimidating for any young robotic sur-
geon. It helps to have a dedicated robotic team, as
familiarization is important not just for the surgeon, but
also for the bedside assistants and scrub team, as well as
the theater staff. The bedside assistant should be familiar
with standardized surgical steps; the scrub team should
be well equipped with all the instruments, sutures, and
staplers required, and the operating theater staff should
be prepared in terms of proper patient positioning and
necessary protection. In an operation of such high com-
plexity, teamwork from all the members of the team in-
volved is crucial, to ensure smooth sailing surgery and
to minimize complications and conversion rate, and
shorten the operating time.
With adequate experience, the refinement of surgical
techniques also contributes to the safety and feasibility
of an intracorporeal neobladder. A hallmark of a good
ileal neobladder is large capacity for storage, low pres-
sure, and high compliance for continence, and the ability
to voluntarily void with minimal residual urine [15]. A
conventional spherical pouch has been proven urodyna-
mically to be of high volume and low pressure and gives
excellent functional outcomes [16]. Various different
types of ileal neobladder have been used in patients who
underwent open radical cystectomy and neobladder re-
construction. One study showed similar perioperative
and functional outcomes using a non-spherical pouch
[17]. Some of these less complicated technique can be
adapted into robotic intracorporeal neobladder construc-
tion and could further shorten the operating time with-
out compromising outcomes.
In our experience, exposure to complex intracorporeal
surgery of a lesser degree such as laparoscopic or robotic
intracorporeal ileal ureter is helpful in familiarization
with the steps involved in intracorporeal bowel resection
and anastomosis [18].
Our results have shown the safety and reproducibility
of this complex technique with comparable operating
time, complications, functional, and oncologic outcomes
to those of the pioneer centers. However, we face similar
limitations to those experienced by previous authors ,
such as retrospective nature, limited number of patients,
and follow-up durations. However, current results seem
to favor robotic cystectomy with intracorporeal urinary
diversion; a conclusion which can only be established
eventually with a randomized study of adequate power.
Conclusions
With the advancement of technology and refinement of
surgical technique, it is a matter of time before more
surgical teams will embark on robotic cystectomy andintracorporeal neobladder construction. A standardized
technique with a dedicated robotic team in a high vol-
ume center makes robotic intracorporeal neobladder
construction a feasible and reproducible technique.
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